Description
The abstract emphasizes that identification of genuine LRRK2 substrates will provide new therapeutic targets, indicating current substrate identification remains incomplete. This knowledge gap limits understanding of LRRK2’s pathogenic mechanisms and development of substrate-based therapies.
Gap type: open_question Source paper: Targeting LRRK2 in Parkinson’s disease: an update on recent developments. (2017, Expert opinion on therapeutic targets, PMID:28443359)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:41.388759+00:00”, “resolution_summary”: “Resolved by hypothesis h-d4ac0303f6: G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain. Supporting evidence includes debate sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-d4ac0303f6”, “title”: “G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain”, “score”: 0.236, “reason”: “5 token overlaps; entity overlap: lrrk2”, “analysis_id”: “SDA-2026-04-25-gapdebate-9180363b7c”, “target_gene”: “LRRK2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.79, “confidence_score”: 0.32, “status”: “proposed”, “pubmed_evidence_ids”: [“23066449”, “34125248”, “34686322”, “35580815”, “35907404”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352”, “title”: “While the study establishes LRRK2 as a lysosomal swelling sensor and notes that lysosomal swelling occurs in LRRK2-linked diseases, it doesn’t directly test whether pathogenic LRRK2 mutations alter this volume-sensing function. This connection is crucial for understanding how LRRK2 mutations cause Parkinson’s disease and related disorders.\n\nGap type: open_question\nSource paper: Lysosomal swelling triggers LRRK2 activity. (2026, bioRxiv : the preprint server for biology, PMID:41427358)”, “score”: 0.53, “reason”: “11 token overlaps; entity overlap: lrrk2, pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867”, “quality_score”: 0.85, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5”, “title”: “The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.\n\nGap type: unexplained_observation\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.445, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.421, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9_20260413-225442”, “title”: “This study identifies oligodendrocytes as drivers of neuroinflammation in PD, contradicting the established paradigm that microglia are the primary neuroinflammatory cells. Understanding this cell-type hierarchy is crucial for targeting the right therapeutic cells.\n\nGap type: contradiction\nSource paper: Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson’s disease via the prosaposin-GPR37-IL-6 axis. (2025, Cell Rep, PMID:39913287)”, “score”: 0.415, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9”, “quality_score”: 0.79, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d”, “title”: “The abstract explicitly questions whether AD’s hallmark pathologies induce cholinergic dysfunction or vice versa. This fundamental causality question is critical for determining therapeutic targets but remains unresolved despite evidence that β-amyloid affects cholinergic receptors.\n\nGap type: open_question\nSource paper: The cholinergic system in aging and neuronal degeneration. (2011, Behavioural brain research, PMID:21145918)”, “score”: 0.41, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}